Vitrotest Europe sp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2020-06-19
Share capital
50,000.00 PLN
Activity description

Vitrotest Europe is a high-technology manufacturer and supplier of enzyme immunoassay kits and raw materials for immunoassays, specializing in ELISA tests for diagnosing infectious diseases, allergies, and cancer. The company develops and manufactures native and recombinant antigens, monoclonal antibodies, and synthetic controls for laboratory tests. They also provide high-quality antibodies and are involved in creating innovative products for biotechnological production.

Registered address
ul. Krakowska 139-155, 50-428 Wrocław, Poland
Email

Financials

Revenue history (in k)

From the notes

Current income tax (CIT due)$2,564

Filing timeliness

1 of 6 financial statements was filed late (for 2021, 60 days late).

  • 202505/07/2026
  • 202427/06/2025
  • 202301/07/2024
  • 202202/07/2023
  • 202113/09/2022
  • 202018/06/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 32%
City · Wrocław6,625 / 13,656
Top 49%
Voivodeship · Dolnośląskie12,465 / 23,844
Top 52%
Country · Poland158,412 / 297,266
Top 53%

Results vs industry

Revenue
This companyUSD 233.35kMedianUSD 56.72kAverageUSD 2.72m
Net profit
This companyUSD 43.74kMedianUSD -1.27kAverageUSD -92.87k
Operating costs
This companyUSD 186.30kMedianUSD 66.48kAverageUSD 2.68m
Assets
This companyUSD 88.35kMedianUSD 134.71kAverageUSD 3.04m

News

Vitrotest Group to participate in MEDICA 2026!

From November 16 to 19, 2026, the world-renowned MEDICA exhibition will take place in Düsseldorf, Germany, traditionally bringing together leading medical industry professionals from more than 70 countries worldwide. During the exhibition, we will showcase a wide range of high-quality in vitro diagnostic products, including ELISA test kits and components for their production -

Recombinant Human Tissue Transglutaminase Successfully Developed for ELISA Applications

We are delighted to introduce our recombinant RP-50 human tissue transglutaminase (tTG), produced in the Escherichia coli expression system. The recombinant antigen demonstrated outstanding performance in the detection of anti-tTG IgA and anti-tTG IgG antibodies. In addition, it showed high stability and excellent reproducibility of assay results, making it a reliable antigen for immunodiagnostic

Vitrotest Group to participate in MEDICA 2025!

From November 17 to 20, 2025, the world-renowned MEDICA exhibition will take place in Düsseldorf, Germany, traditionally bringing together leading medical industry professionals from more than 70 countries worldwide. During the exhibition, we will showcase a wide range of high-quality in vitro diagnostic products, including ELISA test kits and components for their production -

New Matched Monoclonal Antibodies for Mycoplasma hominis Detection in Urogenital Samples

Our team is pleased to introduce matched pairs of monoclonal antibodies specifically targeting surface lipoproteins of Mycoplasma hominis. Designed for high-affinity binding, these antibodies enable sensitive and specific detection in urogenital clinical samples. They are ideally suited for developers of diagnostic tests and research-use-only (RUO) tools focused on reproductive tract infections.

New Matched Monoclonal Antibodies for Giardia lamblia Cyst Antigen Detection

Vitrotest has developed new matched pairs of monoclonal antibodies specific to Giardia lamblia cyst antigens. These antibodies are ideal for use in sandwich immunoassays such as ELISA and rapid tests. They are optimized for use in diagnostic and research assays, and will be of particular interest to manufacturers of in vitro diagnostic kits.

Protein G – new addition to the portfolio

Protein G – new addition to the portfolio

Vitrotest is pleased to announce the expansion of its product portfolio with the introduction of recombinant Protein G. This streptococcal surface protein from Group G is widely used in immunological applications. It serves as an effective tool for the development of affinity purification carriers for antibodies, as well as for conjugation and other

Offer

  • Enzyme immunoassay kits
  • Raw materials for enzyme immunoassays
  • Laboratory diagnostic products

Website technology

Online shop
  • WooCommerce
Website
  • WordPress
Analytics and marketing
  • Google Analytics

Authorized Representatives

Galyna Rayevska age 51 – President of the Management Board

Manner of representation

In the case of a one-person management board, the member of the management board is authorized to represent the company independently. If the management board is multi-member, each member of the management board is authorized to represent the company and act on its behalf independently.

Ownership

OwnerSharesShare valueStake
500$6,753.1150%
500$6,753.1150%

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2020-07-14.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

PurposeGross amount
Aid for SME access to finance — aid for start-ups
$205.1K

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Kleverlab sp. z o.o.
Nutopi sp. z o.o.
Kolasa sp. j.
Erbafarm Naturale sp. z o.o.
Farmabol sp. z o.o.
Medcalm sp. z o.o.
Wytwórnia Chemiczno - Kosmetyczna Finex sp. z o.o.
Domowa Apteczka sp. z o.o.
GMT Genomics S.A.
Amplicon sp. z o.o.

Change history

DateEvent
2023-08-09Share capital increase
2020-07-06Address change
2020-06-19Entered in the register

FAQ

Last updated: 2026-10-07